Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials

About this update from Lantern Pharma Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/dbff27431341d28d3d0e939f60080a0e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lThVQwZZtV.d2MEoN.Su3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dbff27431341d28d3d0e939f60080a0e","width":480,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all primary endpoints.","length":212,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"LP-184 demonstrated clinical benefit in multiple highly aggressive cancers with a 54% disease control rate at or above therapeutic dose levels.","length":143,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Multiple Phase 1b/2 clinical trials are now being planned across cancer indications and supported by 3 FDA Orphan Drug, 2 FDA Fast Track Designations and a Rare Pediatric Disease Designation.","length":191,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Detailed webinar with management and KOL from Fox Chase Cancer Center highlighting the drug-candidate and patient insights can be found at "Inside The Data".","length":167,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":713,"olType":false},{"type":"text","content":"DALLAS, December 03, 2025--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, announced additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 as well as highlights from its recent webinar. The clinical trial demonstrated encouraging durable disease control in 63 heavily pre-treated patients with advanced solid tumors, many of which had DNA damage repair (DDR) pathway deficiencies. The clinical trial met all primary endpoints for safety, tolerability, and established a clear recommended phase 2 dose (RP2D).","length":682,"tagName":"p"},{"type":"text","content":"Building...

More updates from Lantern Pharma Inc.